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Abstract
We hypothesized that mutations in the HCV NS5B polymerase, which occur during infection, may affect RNA-dependent RNA
polymerase (RdRp) activity. NS5B proteins corresponding to a genotype 1a infectious clone and mutants identified in chimpanzees
following inoculation with the clone were expressed and purified and their in vitro RdRp activity was compared to a NS5B genotype 1b
control. A Gln-65-to-His mutation increased RdRp activity by 1.8-fold as compared to the infectious clone. Moreover, this NS5B1a protein
had RdRp activity similar to the NS5B1b control. Three NS5B proteins representing mutations found in another animal had no in vitro RdRp
activity. All mutations were maintained in the majority circulating virus for at least 216 weeks. The results demonstrate that some in vivo
mutations of NS5B directly enhance in vitro RdRp activity. In addition, they suggest that the in vitro RdRp activity of NS5B may not always
reflect in vivo activity within replication complexes.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
HCV is a positive-sense single-stranded RNA virus with
a genome of approximately 9600 nucleotides that chroni-
cally infects at least 4 million people in the USA (Choo et
al., 1991; Thomas, 2000). The genome has a conserved
5UTR with an internal ribosome entry site (IRES) for
translation of a polyprotein consisting of approximately
3011 amino acids (Han et al., 1991; Rijnbrand and Lemon,
2000; Kong and Sarnow, 2002; Otto et al., 2002). A con-
served genomic 3UTR stem loop is essential for virus
replication in vivo and is probably involved in the initiation
of negative-strand synthesis (Kolykhalov et al., 2000; Blight
and Rice, 1997; Yanagi at al., 1999; Friebe and Barten-
schlager, 2002). The viral polyprotein is processed co- and
posttranslationally into the individual structural and non-
structural proteins. The NS5B protein encodes an RNA-
dependent RNA polymerase (RdRp), which has a structure
consisting of fingers, palm, and thumb domains (Ago et al.,
1999; Bressanelli et al., 1999; Lesburg et al., 1999). The
lambda 1 loop of HCV NS5B, which extends from the
fingers to the thumb domain, is unique to RNA-dependent
RNA polymerases and the beta-hairpin toward the catalytic
region is specific for HCV NS5B. In addition to these
characteristics, HCV NS5B has a number of enzymatic and
structural differences from cellular RNA polymerases
which make it a promising target for small molecule anti-
virals.
The cellular and molecular mechanisms favoring HCV
persistence remain undefined. Although many of them are
likely to involve viral–host interactions which affect inter-
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feron-regulated antiviral pathways or the immune system
(Foy et al., 2003), mutations in the viral genome that affect
RNA replication may also be involved. This may include
the NS5B polymerase, 3 or 5 structures of the () or ()
strand RNA, or other viral nonstructural proteins that form
components of the replication complex.
Due to the lack of a small animal model or an efficient
cell-culture system for HCV, much remains to be learned
about the molecular mechanisms of HCV RNA replication.
Nevertheless, recombinant NS5B purified from insect cells
infected with recombinant baculovirus or Escherichia coli
expressed recombinant protein have been used to define
several basic characteristics of the HCV RdRp (Behrens et
al., 1996; Lohmann et al., 1997; Al et al., 1998). The
properties that have been defined include the effects of pH,
salt, and a requirement for either Mg2 or Mn2 (Lohmann
et al., 1998; Ferrari et al., 1999). HCV NS5B can support
either primer-dependent or primer-independent synthesis of
RNA from an HCV template by de novo initiation if the
extreme 98-nt 3-end stem loop of genomic RNA is present
(Lohmann et al., 1998; Zhong et al., 2000; Kao et al., 2000;
Oh et al., 2000; Ranjith-Kumar et al., 2002). GTP stimulates
in vitro NS5B polymerase activity by 50- to 100-fold
through a mechanism that most likely involves a rate-lim-
iting step of initiation (Lohmann et al., 1999). The recent
identification of a GTP binding site on the surface of the
NS5B apoprotein that is distant from the catalytic site raises
the possibility that the enzyme might be regulated alloster-
ically (Bressanelli et al., 2002).
Few studies have examined the in vivo sequence changes
that occur in the NS5B coding region during chronic HCV
infection. The quasispecies nature of isolates from patients
complicates such studies. However, chimpanzees chroni-
cally infected following intrahepatic inoculation with clonal
genotype 1a HCV RNA have a single starting sequence
which facilitates the identification of subsequent mutations
which are maintained in the dominant viral genome
(Kolykhalov et al., 1997; Major and Feinstone, 2000). Two
animals (Ch1535 and Ch1536) which became chronically
infected following inoculation with in vitro transcribed
HCV RNA have been followed over several years and the
dominant virus sequence was determined at 22, 26, 60, 130,
and 216 weeks postinoculation (p.i.) (Major et al., 1999).
Direct sequencing was carried out on overlapping PCR
products covering 100% of the coding region and parts of
the 5 and 3 UTRs. This method of analysis was chosen
because it accurately determines the sequence of the dom-
inant circulating virus.
Four amino acid mutations in the NS5B region were
observed during the first 60 weeks of infection, one in
Ch1535 and three in Ch1536 (Major et al., 1999). A Gln-
65-to-His mutation in the fingers domain appeared after 60
weeks of infection in Ch1535, a His-33-to-Asn mutation in
the lambda 1 loop appeared at 22 weeks, and both a Leu-
36-to-Met mutation in the lambda 1 loop and Asp-135-to-
Asn in the fingers domain appeared after 60 weeks of
infection in Ch1536. All of these mutations were stably
maintained in the dominant circulating virus throughout the
follow-up analysis period (216 weeks p.i.).
In this study, we report the construction of NS5B clones
that mimic the natural mutations observed in chimpanzees
chronically infected with clonal genotype 1a HCV RNA and
the in vitro analysis of RdRp activity of these mutants and
control NS5B proteins. These studies provide evidence that
some mutations occurring in the NS5B region during
chronic infection may result in a major increase in viral
RNA replication. However, our results also indicate that the
in vitro RdRp assays of purified NS5B proteins may not
always reflect their in vivo activity within replication com-
plexes.
Results and discussion
Amino acid sequence comparison of selected NS5B
genotype 1a and 1b proteins
The amino acid sequence of NS5B encoded by the ge-
notype 1a infectious clone (H77; AF009606) was aligned
with two genotype 1b NS5B proteins demonstrated to have
in vitro RdRp activity (Fig. 1). The genotype 1b NS5B
protein used as a control was similar to a previously re-
ported genotype 1b NS5B protein (AJ238799 con1/1b) (Fig.
1) (Lohmann et al., 1997). Consistent with previously de-
scribed differences between other genotype 1a and 1b sub-
types, the 1a and 1b NS5B proteins used in this study were
different at 61 amino acid residues (10.7%) (Fig. 1) (Hage-
dorn et al., 2000).
Expression and purification of NS5B1a proteins encoded
by an infectious clone and mutants occurring during
chronic infection
Vectors to express the NS5B protein encoded by the
genotype 1a infectious clone (designated wild-type) and
mutants appearing during infection were prepared as de-
scribed under Materials and methods. The Gln-65-to-His
mutation (M1) occurred between 26 and 60 weeks of infec-
tion in Ch1535 (Table 1)(Major et al., 1999). In Ch1536 the
His-33-to-Asn mutation (M2) was observed at 22 weeks and
the Leu-36-to-Met plus the Asp-135-to-Asn mutations (M3)
were observed at 60 weeks of infection. At the end of 60
weeks of infection the majority circulating virus in Ch 1536
contained all three of these mutations (M4) (Table 1). All
mutations in both animals were maintained as the majority
circulating virus, as determined by direct sequencing of
PCR products, for at least 216 weeks (4 years postinocu-
lation), indicating that they were stable mutations which had
66 H. Lou et al. / Virology 317 (2003) 65–72
been incorporated into the primary replicating HCV genome
(Major et al., 1999; Major and Feinstone, 2000). To further
verify that these mutations were incorporated into the ma-
jority circulating HCV genome at 216 weeks postinocula-
tion, multiple clones of PCR fragments covering the NS5B
region from each animal were isolated, purified, and
sequenced. In Ch1535, eight of nine clones carried the
Gln-65-to-His mutation (M1), while only one had the
wild-type sequence. In Ch1536, 9/10 clones carried the
mutations at residues 33 and 36 and 1/10 represented the
wild-type sequence, while 9/10 clones carried the muta-
tion at residue 135 and 1/10 represented the wild-type
sequence.
Wild-type and mutant NS5B proteins were expressed in
E. coli and purified as described under Materials and meth-
ods (Al et al., 1998). Approximately 3 to 4 mg of greater
than 90% pure recombinant NS5B was recovered per liter of
culture for all proteins (Table 2 and Fig. 2).
RdRp activity of the NS5B proteins encoded by an
infectious clone and in vivo mutants
To compare the activity of NS5B encoded by the HCV
genotype 1a infectious clone with the mutants of NS5B that
developed during chronic infection, RdRp assays were done
with the respective recombinant NS5B proteins and RNA
templates representing the 3end of HCV genomic RNA.
The HCV NS5B polymerase can use a variety of RNA
templates and includes the 3X-tail of HCV RNA which
permits primer independent de novo RNA synthesis (Zhong
et al., 2000; Luo et al., 2000; Ranjith-Kumar et al., 2002).
We used 3X() HCV RNA as template in the RdRp
assays. The relative RdRp activity of NS5B encoded by the
1a infectious clone was 74% of the NS5B1b control (Fig. 3).
This was consistent with previous reports suggesting that
NS5B proteins from genotype 1a viruses have less RdRp
activity than genotype 1b viruses (Ferrari et al., 1999;
Fig. 1. Sequence alignments are shown for the HCV NS5B polymerase encoded by the genotype la infectious clone (H77, AF009606), the four mutants of
NS5B1a that were identified in chronically infected chimpanzees (M1–M4), the NS5B genotype 1b control protein (5B1b), and a previously reported NS5B1b
protein (Con1, AJ238799). Arrowheads indicate the position of mutations and their location in the recombinant protein. The 21 amino acids at the C-terminus
(underlined) were not present in the recombinant protein and were replaced by a hexahistidine tag of the pET-21a vector to increase protein yields and ease
of purification. Note that the purified recombinant protein has an additional SM at the amino-terminus as compared to the naturally occurring HCV NS5B
protein that is produced by proteolytic processing of the polyprotein (Al et al., 1998).
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Friebe et al., 2002). However, the mutation of Gln-65 of
NS5B, a hydrophilic polar amino acid located on the surface
of the fingers domain, to the hydrophilic basic amino acid
His (M1) resulted in a 1.8-fold increase (P value by t test
0.0001) in RdRp activity relative to NS5B of the infec-
tious clone (Figs. 3 and 4). Moreover, this resulted in a
genotype 1a NS5B protein with slightly more RdRp activity
than the NS5B1b control (Fig. 3). This result provides an
example where a NS5B polymerase encoded by a genotype
1a virus does have in vitro RdRp activity that is at least
equal to a genotype 1b NS5B polymerase and may be useful
in modifying genotype 1a HCV replicons (Blight et al.,
2003).
Previous efforts to identify point mutations that increase
the RdRp activity of a genotype 1a NS5B protein, based on
sequence analysis of 48 viral isolates and altering a specific
isolate toward a consensus sequence, did not result in major
increases in activity (Hagedorn et al., 2000; Hagedorn et al.,
unpublished data). The precise reason why the Gln-to-His
mutation at position 65 enhanced in vitro RdRp activity by
as much as 1.8-fold remains unknown at this time. Never-
theless, the location of Gln-65 in the NS5B crystal structure
is close to the Arg-345 residue which stimulates RdRp
activity two- to threefold when mutated to Lys (Fig. 4)
(Lohmann et al., 1998). It remains to be determined if these
two mutations share a similar mechanism or have indepen-
dent mechanisms which either modify properties of the
proteins in solution or directly increase RdRp catalytic ac-
tivity.
The mutations of NS5B that occurred in Ch1536 and
were maintained in the dominant circulating virus did not
stimulate in vitro RdRp activity. In fact, the NS5B1a-M2
(His-33 to Asn), M3 (Leu-36 to Met plus the Asp-135 to
Asn), and M4 (all three mutations) proteins had essentially
no detectable in vitro RdRp activity (Figs. 3 and 4). This
result remains a puzzle and several possible explanations
can be considered. His-33 is part of the lambda 1 loop of
HCV NS5B, which includes amino acids 11–45 within the
fingers domain and is structurally unique among RNA-
dependent RNA polymerases (Bressanelli et al., 1999; Les-
burg et al., 1999; Ago et al., 1999). This loop forms two
-helical turns which pack closely against helices of the
thumb subdomain (Fig. 5). The lambda 1 loop has been
suggested to participate in the concerted “clamping” motion
of the fingers and thumb domains during the translocation of
a template along the polymerase. His-33 hydrogen bonds to
residue 493 at the C-terminus of helix S in the thumb
Table 1
Mutations of NS5B1a following infection with clonal HCV RNA
Name Animal Amino acid
positiona
Amino acid
change
Nucleotide
change
Mutation appeared
time (weeks)
NS5B1a-M1 Ch.1535 65 Gln-His CAG-CAT 26–60
NS5B1a-M2 Ch.1536 33 His-Asn CAT-AAT 4–22
NS5B1a-M3 Ch.1536 36 Leu-Met CTG-ATG 22–60
135 Asp-Asn GAC-AAC 22–60
NS5B1a-M4 Ch.1536 33 His-Asn CAT-AAT 4–22
36 Leu-Met CTG-ATG 22–60
135 Asp-Asn GAC-AAC 22–60
a See Fig. 1.
Table 2
Purification table: recombinant NS5B1a expressed in E. coli
Volume
(ml)
Protein
concentration
(mg/ml)
Total protein
(mg)
E. coli culture 1000
Lysate 80 30.5 2440
HPLC affinity column 24 0.16 3.5
Note. The data in the table were obtained with the NS5B protein encoded
by the infectious clone (wt) and is representative of the purification of other
recombinant NS5B proteins (M1–M4 and the genotype 1b control). The
yield of E. coli cell pellets was 4 g wet weight per 1000 ml of culture and
“Lysate” represents the 40,000 g supernatant following sonication of cells
in lysis buffer. Details of the purification method are provided under
Materials and methods.
Fig. 2. Expression in E. coli and purification of recombinant HCV NS5B1a
encoded by the infectious clone (wild-type) and mutants that occurred
during chronic infection. The expression and purification of proteins are
described under Materials and methods. Representative stages of expres-
sion and purification were analyzed by 10% SDS–PAGE and the proteins
were stained with Coomassie blue. The gel shown represents: lane 1,
molecular mass standards (97, 66, 45, 35, and 29 kDa); lane 2, uninduced
E. coli lysate; lane 3, IPTG-induced E. coli lysate; lane 4, starting material
prepared from IPTG-induced E. coli cells; lane 5, a representative
flowthrough of purifications; lanes 6–10, purified recombinant NS5B pro-
teins encoded by the infectious clone (lane 6) and mutants that appeared
during chronic infection in two chimpanzees (M1–M4 in lanes 7–10,
respectively; see Table 1). The NS5B1b control protein was purified by the
same method and was of similar purity (not shown).
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domain and may be a critical element in the interaction
between the fingers and thumb domains (Bressanelli et al.,
1999). In addition, this site of interaction is also close to the
GTP binding pocket that has been proposed to regulate
NS5B allosterically (Bressanelli et al., 2002). Leu-36,
within the lambda 1 loop, also participates in the fingers–
thumb interaction. Previous studies have also shown that
deletion of the first 40 residues of NS5B resulted in com-
plete loss of RdRp activity (Lohmann et al., 1998). In
Fig. 3. RdRp activity of recombinant NS5B1a polymerase encoded by an infectious clone and mutants that occurred during chronic infection as compared
to a NS5B1b control protein. The synthesis of [32P]UTP-labeled RNA (mean SEM; n 6) from a HCV 3X () template is shown in the bar graph. RdRp
assays were as described under Materials and methods.
Fig. 4. Gel analysis of RNA products. RNA products from RdRp assays
using HCV 3X() RNA as template (98 nt in length), incubated at 30°C
for 1 h, were analyzed by 5% polyacrylamide–7 M urea gel electrophoresis
and autoradiography (see Materials and methods). The autoradiogram from
a representative experiment (done three times) is shown: lane 1, control
incubation with no NS5B added; and complete incubations with the spec-
ified NS5B protein (lanes 2 to 5; as described under-Materials and meth-
ods). The locations of RNA markers (Novagen) are shown.
Fig. 5. Location of the mutations in the HCV NS5B polymerase. A ribbons
diagram of NS5B (finger, palm, and thumb domains colored red, yellow,
and blue, respectively) is shown depicting the location and side chains of
the His-33, Leu-36, Gln-65, and Asp-135 residues that were mutated and
studied. Note that the location of Gln-65, which stimulated RdRp activity
when mutated to His, is close to another site (Arg-345), which stimulates
activity when mutated to Lys (Lohmann et al., 1998).
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addition, both Glu-18 and Leu-30 within the lambda 1 loop
have been reported to be critical for in vitro RdRp activity
(Labonte et al., 2002; Qin et al., 2002). However, all of the
NS5B mutations observed in Ch1536 were present in the
majority circulating virus and were stably maintained as the
consensus sequence for at least 4 years postinfection, sug-
gesting the resulting NS5B protein is expressed by replicat-
ing viruses and has sufficient in vivo RdRp activity to
maintain a chronic infection. We suggest that recombinant
NS5B in solution may be particularly sensitive to changes in
residues that participate in the fingers–thumb interactions
and that when NS5B is anchored within a replication com-
plex in vivo the specific mutations discussed do not disrupt
RdRp activity to the same degree. On the other hand,
changes at the M2–4 sites may modify NS5B:NS5B inter-
actions and oligomerization (Table 1) (Wang et al., 2002).
Another possible explanation is that mutations identified in
the NS3 and NS5A proteins, which are predicted to be
present in replication complexes, are compensatory and
attenuate the in vivo effect of the mutations at residues 33,
36, and 135 of NS5B (Major et al., 1999). We are in the
process of further testing the effect of these mutations on
HCV RNA synthesis in a cell-based replicon system.
The events that control clearance of HCV or progression
to persistent infection have not been identified. There are
indications that stronger and broader T cell responses during
the acute phase of infection correlate with clearance. How-
ever, functional studies of mutations identified during
chronic infection using clinical isolates are complicated by
the presence of quasispecies and the inability to distinguish
nonfunctional viral sequences from those contributing to
replication. On the other hand, inoculation of chimpanzees
with cloned HCV RNA permits a clear identification of
mutations that occur during chronic infection. Our results
demonstrate that some mutations which develop in the
NS5B coding region during chronic HCV infection may
have major implications for the efficiency of HCV RNA
replication and viral persistence.
Stable amino acid mutations observed in other regions of
serum-derived HCV RNA from Ch1535 and Ch1536 have
been identified and are likely to include other components
of the replication complex. Mutations in NS3 (A1533P and
V1635I) identified at week 26 in Ch1535 and NS3
(R1181K) arising at week 22 and NS5A (T2349A and
A2412T) identified at week 60 in Ch1536 have been de-
scribed (Major et al., 1999). These changes may represent
adaptive mutations that complement those identified at res-
idue 33, 36, and 135 in NS5B to achieve effective RNA
replication. Complementary mutations have been identified
in the NS3 and NS5A regions during cell culture of HCV
subgenomic replicons (Blight et al., 2000; Krieger et al.,
2001). In addition, several of the mutations observed in
Ch1535 and Ch1536 during the early phase of infection
could confer CTL escape (Major and Feinstone, 2000).
Adaptive mutations in other proteins involved in the repli-
cation complex might be needed to maintain virus survival.
The NS3 residue at position 1635 has been previously
identified as part of a cytotoxic lymphocyte (CTL) epitope
in chimpanzees, although the V1635I change has not been
confirmed as a CTL escape mutant in Ch1535 (Cooper et
al., 1999). Although the in vivo biological role for the stable
mutations in the NS5B region observed during chronic
HCV infection of chimpanzees remains to be determined,
the ability of at least one of them to produce major changes
of in vitro RdRp activity may have practical implications for
the design of small molecule therapeutics targeting the
NS5B polymerase (De Francesco et al., 2003; Gu et al.,
2003; Dhanak et al., 2002). Our results suggest that further
studies of NS5B mutations which occur in model systems or
patients with chronic hepatitis C are warranted.
Materials and methods
Construction of expression plasmids
The pET-21a vector (Novagen, Madison, WI) was used
to express recombinant NS5B with a C-terminus hexahisti-
dine tag in E. coli following previously described methods
(Al et al., 1998). A full-length NS5B cDNA of HCV geno-
type 1a corresponding to the sequence of the original infec-
tious cDNA clone used to inoculate the chimpanzees was
cloned into pCR2.1 (Invitrogen) and used as a template in
these studies (Kolykhalov et al., 1997; Major et al., 1999;
Major and Feinstone, 2000). The NS5B-region was amplified
by PCR using the following primers: 5-TTATTGGATCCA
TGGCTAGCATGTCTTATTCCTGGACAGGCGC-3 (for-
ward pr imer ) , 5  -AACATCTCGAGGCGGGGC
CGGGCATGAGACACG-3 (reverse primer). The under-
lined sequences represent the NheI and XhoI subcloning
sites, respectively. The final PCR product was cloned into
pET-21a downstream of the T7 RNA polymerase promoter
using the NheI and XhoI sites. The C-terminal 21 amino
acids of NS5B were deleted to produce a more soluble
recombinant protein (Ferrari et al., 1999). This construct
was used as a template to introduce the point mutations into
HCV NS5B1a observed in the chronically infected chim-
panzees. NS5B1a with substitution of Gln-65 with His was
designated M1; substitutions of His-33 with Asn, Leu-36
with Met, and Asp-135 with Asn were designated M4;
substitution of His-33 with Asn was designated M2; and
substitutions of Leu 36 with Met and Asp-135 with Asn
were designated M3 (Table 1 and Fig. 1). These mutations
were produced by site-directed mutagenesis and were con-
firmed by sequencing as previously described (Spivak-
Kroizman et al., 2002). An NS5B genotype 1b expression
vector was used as a control. The amino acid sequences of
the NS5B isolates were aligned using CLUSTAL W soft-
ware (Thompson et al., 1994).
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Expression and purification of the recombinant NS5B
protein
NS5B1a (infectious clone), M1, M2, M3, M4, and
NS5B1b proteins were expressed in E. coli strain BL21
(DE3) following previously described methods (Al et al.,
1998). BL21 cells were grown to an OD600 of 0.5 at 37°C
in TB medium containing carbenicillin and protein expres-
sion was induced at 25°C for 6 h with 1 mM IPTG. Cell
pellets were suspended in lysis buffer (50 mM HEPES, 400
mM NaCl, 10% glycerol, 0.1% NP-40, 1 mM PMSF, 10
g/ml each of aprotinin, leupeptin, pepstatin A, and 0.1 mM
benzamidine; pH 8.0) and sonicated or lysed using a French
Press and centrifuged for 30 min at 40,000 g. The superna-
tant was applied to a FPLC TALON Superflow Metal Af-
finity Column (Clontech). The resin was washed and the
recombinant proteins were eluted with an imidazole gradi-
ent (1 to 500 mM). The eluted protein was dialyzed against
50 mM HEPES, 300 mM NaCl, 10% glycerol, 0.1% NP-40,
1 mM DTT (pH 8.0) and stored at 80°C. Proteins were
analyzed by 10% SDS–PAGE and quantitated using a Bio-
Rad protein assay.
Preparation of RNA templates
To prepare HCV RNA templates, a full-length serum-
derived clone of HCV in pGEM-T (Promega) was used. The
HCV 3 98-nt stem loop of genomic HCV RNA designated
3X () was used in these studies. The following primer
sets were used to amplify PCR products for T7 RNA poly-
merase synthesis of RNA templates: forward primer 5-
AGTTAATACGACTCACTATAGGGAGGTGGCTCC-3
and reverse primer 5-GAGTACTTGATCTGCAGAGAG-
GC-3 for 3X (). The T7 RNA polymerase promoter
sequence is underlined. The RNA templates were synthe-
sized with T7 polymerase using conditions suggested by the
manufacturer (Epicentre Technologies). The RNA tran-
scripts were treated with DNase I, phenol-chloroform ex-
tracted, and ethanol precipitated. RNA was analyzed by 1%
agarose gel electrophoresis.
RdRp assay
RdRp assays were performed in 50-l incubations con-
taining 50 mM HEPES (pH 8.0), 5 mM MnCl2, 4 mM DTT,
0.5 mM each ATP, CTP, and GTP, 5 Ci of [-32P]UTP
(Amersham Biosciences), 200 ng of RNA template, and 500
ng of the purified NS5B as described elsewhere (Al et al.,
1998). The reaction mixtures were incubated at 30°C for
1 h. The RNA synthesized was precipitated by adding 10 g
of calf thymus DNA plus 7% trichloroacetic acid (TCA) and
incubated on ice for 30 min. The synthesized RNA was
collected by using GF/C glass filters (Whatman) and
washed with pyrophosphate followed by 95% ethanol. The
amount of radioactivity bound to each filter was determined
by liquid scintillation counting. RNA products were also
analyzed by electrophoresis using a 5% denaturing poly-
acrylamide–7 M urea gel and autoradiography.
Cloning and sequencing of PCR product
PCR products covering the NS5B region containing the
observed mutations were generated as previously described
(Major et al., 1999). The PCR fragments were cloned into
the pCR2.1 TA cloning vector (Invitrogen, Carlsbad, CA)
according to the instructions of the manufacturer. Positive
clones were determined by restriction enzyme digestion
with EcoRI and sequenced using the PE Applied Biosys-
tems Dye Terminator Cycle Sequencing FS reaction mix
according to the instructions of the manufacturer (PE Ap-
plied Biosystems, Foster City, CA). Sequences were com-
pared using DNAStar Seqman software (DNAStar Inc.,
Madison, WI).
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